Mestinon
In brief
- Mestinon is a prescription-only medicine (POM) in the UK.
- Mestinon is used for the treatment of myasthenia gravis, and it works as an anticholinesterase inhibitor, enhancing communication between nerves and muscles.
- The usual dosage for adults is 30-60 mg taken orally 3-4 times daily, with adjustments based on individual needs.
- The form of administration is oral tablets.
- The onset time for Mestinon is typically within 30 to 60 minutes.
- The duration of action is approximately 4 to 6 hours.
- The most common side effect of Mestinon is increased salivation.
- Would you like to try Mestinon without a prescription?
Basic Mestinon information
- INN (international nonproprietary name): Pyridostigmine
- Brand names available in the United Kingdom: Mestinon
- ATC code: N07AA02
- Forms and dosages: Tablets 60 mg
- Manufacturers in the United Kingdom: Bausch Health
- Registration status in the United Kingdom: Prescription-only medicine (POM)
- OTC / Rx classification: Prescription-only medicine (POM)
Morning vs evening dosing
Mestinon is a key medicine for people with myasthenia gravis. It is taken in several doses spread through the day, so that its effect stays steady. Doses are usually timed so that the effect is strongest when it is most needed, for example before getting up, before meals and before physical activity. Your specialist will advise on the timing that suits you.Taking with or without meals
Mestinon can be taken with or without food. Taking it with food can reduce stomach upset such as nausea, and for people who have difficulty chewing or swallowing, a dose taken about 30 to 60 minutes before a meal can make eating easier. Building the doses into a daily routine helps you keep to the schedule.Who should avoid it (MHRA warnings)
Patients with mechanical obstruction of the gastrointestinal or urinary tract should not take pyridostigmine. It must also not be used by anyone who is hypersensitive to pyridostigmine, bromides or any of the other ingredients.Activities to limit (driving, work safety)
Potential side effects associated with Mestinon, such as muscle twitching and mild bradycardia, warrant careful consideration regarding daily activities. Patients should limit tasks like driving or operating heavy machinery, particularly during the medication's initial adjustment phase. Check with a healthcare professional before resuming these activities; they can give advice for your circumstances.Dosage and adjustments
For adults, the initial dose is typically 30–60 mg taken orally in 3 to 4 doses daily, with the total daily amount often in the range of 180–540 mg. The dose is set individually by the specialist and adjusted according to response.
General regimen (NHS guidance)
Follow the dosing schedule set by your specialist. Adjustments are common, as some people respond more quickly than others. Key points:
- Initial dosage often starts low to monitor tolerance.
- Healthcare professionals routinely review effectiveness and potential side effects.
- It’s key to keep medication consistent to maintain muscle strength and minimise symptoms of myasthenia gravis.
Special cases (elderly, comorbidities)
The elderly generally require a careful approach to medication management. Starting with lower doses is often advisable due to their heightened sensitivity to medications.
For those with renal impairment, vigilance in monitoring is crucial, as improper dosing can lead to drug accumulation and toxicity.
For children, the dose is set by a specialist according to age and weight.
What’s inside and how it works
Ingredients overview
Mestinon contains pyridostigmine as its active ingredient, classified as an anticholinesterase agent. Additional inert excipients are included to ensure the stability and strength of the tablet form.
Mechanism basics explained simply
Pyridostigmine operates by blocking the breakdown of acetylcholine, a neurotransmitter that plays a crucial role in muscle contraction. This inhibition enhances communication between the nerves and muscles, leading to improved muscle strength and function for individuals dealing with myasthenia gravis.
Main indications
Approved uses
Mestinon is licensed in the UK for the treatment of myasthenia gravis, a chronic autoimmune condition that disrupts nerve-to-muscle communication and causes fluctuating muscle weakness.
Off-label uses in UK clinics
While its main use is for myasthenia gravis, there are instances where specialists may prescribe Mestinon for off-label purposes, such as certain congenital myasthenic syndromes, under the supervision of a specialist.
Delivery time overview
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Manchester | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Newcastle | England | 9–21 days |
| Nottingham | England | 9–21 days |
| Brighton | England | 9–21 days |
| Southampton | England | 9–21 days |
| Coventry | England | 9–21 days |
| Cardiff | Wales | 9–21 days |
